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466Objective: The Thoratec (Thoratec Corp, Pleasanton, Calif) implantable ventricular assist device (IVAD) can be
used for univentricular or biventricular support. The objective of this study is to review the 5-year experience of
bridging patients to heart transplantation with this device in a single center. Surgical aspects, including hybrid
pump pocket, double tunneling of driveline, and optimal cannulae placement, are discussed.
Methods: This is a retrospective review of 24 patients treated between January 2002 and December 2007. Nine-
teen patients (79.1%) received a single implantable ventricular assist device as left ventricular assist devices, and
5 patients (21.9%) received 2 implantable ventricular assist devices as biventricular assist devices. The devices
were implanted in pre-peritoneal/posterior rectus hybrid pump pockets. The driveline was passed through a
2-stage double-tunnel to exit onto the lateral chest wall. Patients were anticoagulated with Warfarin aiming
for an international normalized ratio of 2.0 to 3.0.
Results: Twenty male and 4 female patients with a mean age of 39.8 years (17–57 years) and a body surface
area of 1.87 m2 (1.63–2.2 m2) were supported for a total of 2308 patient-days. Mean duration of support was
96 days (10–301 days). The cause of heart failure was dilated cardiomyopathy in 18 patients and ischemic
cardiomyopathy in 6 patients. Preoperatively, 23 patients were receiving inotropes, 12 patients required
intra-aortic balloon pump support, 5 patients were intubated and mechanically ventilated, and 3 patients re-
quired continuous venovenous hemofiltration for renal support. Eleven patients (45.8%) were discharged
with ventricular assist device support (1015 home patient-days). Complications observed were a) neurologic:
stroke in 3 patients, transient ischemic attacks in 4 patients; and b) infection: driveline infection in 3 patients
and pump pocket infection in 1 patient. There was no mechanical device failure. Support to transplantation was
achieved in 17 patients (70.8%): 3 of 5 biventricular assist devices (60%) and 14 of 19 left ventricular assist
devices (73.7%).
Conclusion: The Thoratec IVAD is a versatile and reliable ventricular assist device. It can provide univentricular
or biventricular support for bridging patients to heart transplantation with acceptable complication rates. The
portable Thoratec TLC-II console facilitated discharge while patients waited for a suitable donor heart. (J Thorac
Cardiovasc Surg 2010;139:466-73)Considerable progress has been made during the last 2 de-
cades in the development of ventricular assist devices
(VADs). Initially, failure to wean from cardiopulmonary by-
pass (CPB) was the primary indication for VAD support.1-5
The role of VADs then expanded to bridging patients to car-
diac transplantation.6-10
The Thoratec (Thoratec Corp, Pleasanton, CA) paracor-
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The Journal of Thoracic and Cardiovascular Surgof many mechanical circulatory support programs with
more than 4000 implants in patients worldwide. The newer
Thoratec implantable ventricular assist device (IVAD) was
designed to have a blood path identical to that of the
PVAD system.11,12 The IVAD underwent a regulatory trial
and was approved in 2004.13 This article reports the clinical
experience with the Thoratec IVAD as a bridge-to-trans-
plant device in a single institution. Surgical aspects specific
to the Thoratec IVAD and potential technical pitfalls are
discussed.PATIENTS AND METHODS
Clinical records of all patients implanted with the Thoratec IVAD at Pap-
worth Hospital between January 2002 and December 2007 were retrospec-
tively reviewed. This study was approved by the local research ethics
committee. Data collected and analyzed include patient medical history, de-
mographics, hemodynamics, blood parameters pre- and post-VAD implan-
tation, adverse events, and outcome. The primary end point was survival to
heart transplantation.ery c February 2010
Berman et al Cardiothoracic TransplantationAbbreviations and Acronyms
BVAD ¼ biventricular assist device
CPB ¼ cardiopulmonary bypass
CVVH ¼ continuous venovenous hemofiltration
IVAD ¼ implantable ventricular assist device
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
PVAD ¼ paracorporeal ventricular assist device
RV ¼ right ventricular
RVAD ¼ right ventricular assist device
VAD ¼ ventricular assist deviceFIGURE 1. Computed tomography scan of a patient with biventricular
Thoratec (Thoratec Corp, Pleasanton, Calif) IVAD support illustrating dou-
ble tunneling of the drivelines and exit in the left lateral chest wall. A, Small
transverse skin incision in lower abdomen quadrant. B, Stab incision on lat-
eral chest wall for driveline exit. The driveline is pulled from pump pocket
through to A and then taken through a subcutaneous tunnel from A to B.
T
XSurgical Implantation
All IVADs were implanted through a median sternotomy incision. Gen-
erally, the VAD pump pocket was created, and the driveline was pulled
through the subcutaneous tunnel before systemic anticoagulation.
Hybrid Pump Pocket
A median sternotomy incision is extended onto the linea alba for 5 cm.
The pre-peritoneal fat is dissected away from the posterior rectus sheath lat-
erally for 3 cm. This forms the medial half of the pump pocket. A longitu-
dinal incision is made along the full length of the posterior rectus sheath
approximately 3 cm lateral to the linea alba. A new dissection plane is
then developed laterally between the rectus abdominis muscle and the pos-
terior rectus sheath, continuing deep to the external oblique muscle, provid-
ing the lateral half of the ‘‘hybrid’’ pump pocket. The pump pocket extends
laterally to the apex of the heart and inferiorly to the level of the iliac crest.
The anterior small muscles between the diaphragm and the costal margin are
divided between ligatures or surgical clips. The IVAD sizer is used to assess
the pump pocket volume, taking care to verify that the tips of the pump caps
lie just below the level of the diaphragm.
Two-Staged Double Tunnel for the Driveline
To facilitate tunneling of the IVAD driveline, a 3-cm transverse skin in-
cision is made in the lower abdominal wall just below the level of the ante-
rior superior iliac spine. For the final driveline exit site, a separate stab
incision is made in the skin at the level of the fifth or sixth rib along the
left anterior axillary line. The driveline is first tunneled from the pump
pocket caudally through the rectus muscle to the lower abdominal incision.
It is then directed back into the wound and tunneled in the subcutaneous tis-
sues cranially toward the stab incision at the chosen driveline exit site
(Figure 1). This creates a long tunnel gently curving through 180 degrees
at the lower end, increasing the length of the tissue ingrown barrier to infec-
tion. The pre-primed IVAD is seated in the pump pocket by caudal traction
on the driveline through the lower abdominal incision. The connector for the
driveline is assembled after the driveline has been exteriorized. The pneu-
matic and electrical leads can then be connected and the ends handed out
ready for connection to the external drive console. Once the position of
the driveline is finalized, the transverse incision on the lower abdominal
wall is closed.
Cardiopulmonary Bypass Strategy
All IVAD implants were conducted using normothermic CPB and full-
dose aprotinin. (Since July of 2008, aprotinin is no longer available for
use in the United Kingdom.) The lungs were continuously ventilated with
tidal volumes of 10 mL/kg and 10 parts per million of nitric oxide through-
out to prevent atelectasis and to dilate the pulmonary vasculature. Base ex-
cess was maintained at 2 mEq, and hemoglobin was maintained at moreThe Journal of Thoracic and Cathan 10 g/dL. The pericardial space is flooded with carbon dioxide at
2 L/min. No aortic crossclamp or cardioplegia arrest was used.
Implantable Ventricular Assist Device Outflow
Cannulation
The IVAD outflow cannula consists of a curved Thoralon (Thoratec
Corp, Pleasanton, Calif) polyurethane tubing and a length of Dacron vascu-
lar graft which is pre-clotted with a mixture of blood and fresh-frozen
plasma before use. The graft is cut to the correct length and anastomosed
end to side to the ascending aorta with a continuous 5-0 Prolene suture.
Implantable Ventricular Assist Device Inflow
Cannulation
The anterior aspect of the left ventricular (LV) apex is exposed and cored,
removing approximately 0.5 cm diameter of myocardium for histology. The
ventricular chamber is inspected for mural thrombus and prominent trabe-
culae, which are removed. The IVAD inflow cannula has a 45-degree curve
in its extracardiac segment. The tip of the inflow cannula should be inserted
into the left ventricle with the extracardiac part pointing caudally (ie, toward
the patient’s feet). The sewing ring is secured to the ventricle using 8 horizon-
tal mattress Teflon felt pledgeted 2-0 Ethibond stitches. A silicone membrane
is used to minimize adhesions to the pericardium. After returning the apex to
the anatomic position, the intraventricular end of the IVAD inflow cannula
should be directed at the mitral valve (ie, posteriorly and medially). Care
must be taken to maintain this orientation when the extracardiac end of the
inflow cannula is attached to the IVAD (Figure 2, A, B).
The outflow cannula is connected to the IVAD with the curve directed
toward the patient’s right side. A de-airing cannula is inserted in the vascular
graft of the outflow cannula and connected to a cardiotomy sucker. Beforerdiovascular Surgery c Volume 139, Number 2 467
FIGURE 2. Computed tomography scan of 2 Thoratec IVAD recipients.
A, Optimal orientation of inflow cannula. B, Malrotation of the inflow
cannula.
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Xthe patient is weaned from CPB, the right ventricle is routinely supported
with dopamine at 5 mg/kg/min. The heart is filled to a central venous pres-
sure of 10 mm Hg, and as the heart begins to eject, bypass flow is reduced.
Meticulous de-airing is achieved by slow hand pumping of the IVAD,
guided by transesophageal echocardiography. When de-airing is complete,
the IVAD driveline is connected to a Thoratec dual drive console, which is
set to the automatic mode (fill-to-empty) with initial drive pressure of 80
mm Hg. The console vent is opened to air; vacuum is not used to assist
VAD filling to avoid air entrainment. As filling of the left ventricle im-
proves, the drive pressure is increased stepwise until it is 75 to 100 mm
Hg above the systolic pressure of the patient to ensure complete emptying
of the IVAD. CPB is discontinued, and heparin is fully reversed with prot-
amine sulphate.
The pericardium is closed, either directly or with a strip of silicone sheet.
Two intrapericardial drains are placed with further Redivac HVS drains
(Medinorm, Spiesen, Germany) in the pump pocket and the retrosternal
space. Externally, 2 Hollister Tube Attachment Devices (Hollister Inc, Lib-
ertyville, Ill) with cable ties are used to secure the drivelines on the chest wall.
Right Ventricular Assist Device Placement
If LVAD flows of 2.0 L/min/m2 could not be achieved with central
venous pressure of less than 16 mm Hg, early consideration was given to
insert a second IVAD as a right ventricular assist device (RVAD).
A hybrid pump pocket is created in the right upper quadrant as described.
The RVAD driveline is tunneled to run alongside the LVAD driveline, ex-
iting 2 to 3 cm lateral to the LVAD driveline exit site (Figure 1). An atrial
cannula designed for the IVAD is inserted in the body of the right atrium and
secured with two 4-0 Prolene pledgeted pursestring sutures. The outflow
graft is pre-clotted, cut to length, and anastomosed end to side to the pulmo-
nary trunk with a continuous 5-0 Prolene suture. In this configuration, the
IVAD has to be positioned in the pump pocket back to front so that the
VAD inflow is on the righthand side and the outflow is near the midline.
As an alternative to right atrial cannulation for RVAD inflow, the right ven-
tricle can be cannulated with a curved IVAD ventricular inflow cannula.
De-airing and weaning from CPB are performed as above.
Anticoagulation Management
Anticoagulation is omitted for the first 24 hours. Heparin infusion is only
commenced when pericardial drainage is less than 25 mL/h for 3 consecu-
tive hours, aiming for a partial thromboplastin time of 1.5 to 2.0 times of
control. Oral warfarin was started after day 5 when patients were able to tol-
erate oral medication, aiming for an international normalized ratio of 2.0 to
3.0. Heparin infusion is discontinued when international normalized ratio is
greater than 2.0. Antiplatelet agents were not routinely used. Aspirin at 150
mg once daily was only introduced for patients who experienced transient
ischemic attacks despite adequate anticoagulation.
Device Choice
The choice of device has obviously evolved over time as new devices be-
come available. More recently, the majority of patients received continuous
flow devices either as a bridge to transplant (VentrAssist; Ventracor Ltd,
Chatswood, Australia) or bridge to decision (Levitronix CentriMag; Levi-
tronix, Waltham, Mass). However, for patients in whom there is a concern
that biventricular support might be required, especially those with intracta-
ble ventricular arrhythmia or established end-organ failure, the use of Thor-
atec VADs is favored. In this latter group of patients, those who are stable
enough to tolerate pump pocket dissection before CPB would receive the
Thoratec IVAD; for patients who are hemodynamically unstable and
required early institution of CPB, the Thoratec PVAD would be used.
Analysis
Data are expressed as mean  standard deviation. Data were analyzed
univariately by unpaired student t test for continuous variables and byery c February 2010
TABLE 2. Patient pre-implant support
Parameter N (%)
Other organ failing 8 (33%)
Pre-VAD IABP 12 (50%)
Pre-VAD CVVH 3 (12.5%)
Pre-VAD ventilation 5 (20.8%)
VAD, Ventricular assist device; IABP, intraaortic balloon pump; CVVH, continuous
venovenous hemofiltration.
Berman et al Cardiothoracic Transplantation
Xchi-square or Fisher’s exact test for categoric variables between the groups
using a commercially available statistics package: Statview (ver5.0, SAS
Institute Inc, Cary, NC).
RESULTS
Baseline Demographics
Between January 2002 and December 2007, 99 patients
were implanted with VADs: 29 Levitronix CentriMags, 12
Impellas (Abiomed, Aachen, Germany), 24 IVADs, 20
PVADs, 4 HeartMate XVEs (Thoratec Corp), and 10
VentrAssists (Ventracor Ltd).
Of the 24 patients who were implanted with the Thoratec
IVAD as a bridge to transplant, 19 (79.1%) received 1
IVAD as a left ventricular assist device (LVAD) and 5
(21.9%) received 2 IVADs as biventricular assist devices
(BVADs) (Tables 1 and 2). There were 20 male and 4 female
patients with a mean age of 39.8 years (17–57 years) and
a body surface area of 1.87 m2 (1.63–2.2 m2). Underlying
disease was idiopathic dilated cardiomyopathy in 17 pa-
tients, ischemic cardiomyopathy in 6 patients, and dilated
cardiomyopathy associated with Becker muscular dystrophy
in 1 patient. Preoperatively, 23 patients were receiving ino-
tropic support, 12 patients required intra-aortic balloon
pump, 3 patients were receiving continuous venovenous
hemofiltration (CVVH), and 5 patients were intubated and
mechanically ventilated for pulmonary edema.
Outcome and Duration of Support
Support to transplantation was achieved in 17 patients
(70.8%): 14 of 19 LVADs (73.7%) and 3 of 5 BVADs
(60%) (Figure 3, A). Cumulative IVAD support duration
for the whole group was 2308 patient-days (6.48 patient-
years), with an average support time of 96 days (10–301
days). For those successfully bridged to transplant, the
mean duration of support was 106 days (10–301 days); for
those who died on support, the mean duration of support
was 57 days (12–154 days). Eleven patients (45.8%) were
discharged with VAD support using the portable Thoratec
TLC- II driver and remained at home for a total of 1015TABLE 1. Patient clinical status
Parameter Mean (±SD)
Age (y) 39.4 (13.6)
Pre-VAD CI (L/min/m2) 1.67 (0.5)
Pre-VAD CVP (mm Hg) 17.9 (7.2)
Pre-VAD mPA (mm Hg) 35.2 (10.1)
Pre-VAD PCWP (mm Hg) 27.5 (5.9)
Pre-VAD creatinine (mmol/L) 114.2 (29.5)
Pre-VAD bilirubin (mmol/L) 44.1 (24.9)
Pre-VAD albumin (g/L) 29 (5.3)
Pre-VAD ALT (U/L) 275 (81)
ALT, Alanine aminotransferase; CI, cardiac index; CVP, central venous pressure; PA,
pulmonary artery; IABP, intraaortic balloon pump; CVVH, continuous venovenous
hemofiltration; VAD, ventricular assist device; mPA, main pulmonary artery; PCWP,
pulmonary capillary wedge pressure; SD, standard deviation.
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Thome patient-days (2.78 patient-years) (Figure 3, B). Of the
13 patients who were not discharged, 4 died in the intensive
care unit, 3 died on the ward, and 6 were bridged to heart
transplant. Those who died in hospital had adverse events
and were never well enough to consider hospital discharge.
The reasons for non-discharge in those who underwent trans-
plantation were as follows: a suitable donor heart became
available very soon after the patients were fit for transplant
(n¼3) and a lack of social/family support at home precluding
home discharge until after heart transplant (n ¼3).
Adverse Events
The majority of adverse events occurred within 30 days of
VAD implantation, and mostly while the patients were still
in hospital.
Bleeding
Six patients underwent re-sternotomy for bleeding,
mostly for cardiac tamponade within the first few days of
VAD implant. Of these 6 patients, only 2 survived to trans-
plantation. A hemothorax developed in 1 patient after a cen-
tral venous line exchange, requiring a thoracotomy to
control the bleeding.
Cannula Malposition
One patient had persistently poor LVAD flow early after
LVAD insertion. This was associated with high pulmonary
capillary wedge pressure and a full left ventricle on echocar-
diography. The problem was due to the IVAD being placed
in too small a pump pocket and the inflow cannula wrongly
pointing toward the lateral wall of the left ventricle. This
patient required revision surgery to shorten and rotate the
inflow cannula to improve LV drainage.
Right Ventricular Failure
Late right ventricular (RV) failure developed in 2 of the
19 patients receiving LVADs, requiring temporary RVAD
support with the Levitronix Centrimag (10.5%). The first
of these patients was initially reexplored for tamponade on
day 8 post-LVAD. Despite decompressing the heart, RV
function remained poor with inadequate LVAD filling. A
temporary RVAD was therefore inserted. Acute onset of
abdominal pain developed in the second patient 10 days
post-LVAD and metabolic acidosis, requiring an emergency
laparotomy and hemicolectomy for ischemic bowel. Hisrdiovascular Surgery c Volume 139, Number 2 469
FIGURE 3. A, Actuarial 6-month survival: underwent heart transplant or remain on VAD support and eligible for transplantation. B, Individual patient de-
tailed VAD support time, including the preoperative and postoperative hospitalization period and home support. *Patients died while being VAD supported.
The remaining patients were bridged to transplant.
Cardiothoracic Transplantation Berman et al
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Xcondition remained poor after the laparotomy and RV func-
tion gradually deteriorated, requiring RVAD insertion the
following day. Despite biventricular support, both patients
subsequently died of multiorgan system failure.
Infection
Driveline infection occurred in 3 patients (0.47 driveline
infections/patient-year of support). All responded well to an-
tibiotic treatment, and none went on to develop pump pocket
infection. Pump pocket infection refractory to medical treat-
ment developed in 1 patient. He eventually died of sepsis.
Neurologic Complications
Three of the 24 patients had a stroke (0.47 strokes/patient-
year of support). One patient had a spontaneous intracranial
hemorrhage on day 95 post-LVAD that was fatal. Two pa-
tients had computed tomography-proven cerebral emboli:
One made a complete recovery and underwent successful470 The Journal of Thoracic and Cardiovascular Surgtransplantation, and one died on support. Four other patients
had 6 episodes of transient ischemic attacks (0.94 transient
ischemic attack/patient-year of support). All of them recov-
ered and were successfully bridged to transplant. At the time
of these neurologic events, all patients had international nor-
malized ratios that were within therapeutic range.Renal Failure
Severe renal dysfunction occurred in 9 patients (37.5%),
who required CVVH. Four patients recovered and under-
went successful heart transplant; the other 5 patients died
while on VAD support.Abdominal Complications
Two patients had abdominal complications; one required
a left hemicolectomy for bowel ischemia 10 days post-
LVAD placement (see above), and one had clinicalery c February 2010
TABLE 3. Descriptive outcome comparison between the Papworth
Hospital implantable ventricular assist device experience and the
multicenter implantable ventricular assist device Thoratec study15
Papworth series
(n ¼ 24)
Multicenter study
(n ¼ 39)
Indications All BTTDCM ¼
18IHD ¼ 6
BTT ¼ 30PC ¼ 9
Mean duration of
support (d)
BTT 96 (10–301) BTT 108 (9–597) PC
77 (14–250)
Total duration of
support
2305 patient-d (6.31
patient-y)
3938 patient-d (10.8
patient-y)
Home discharge
(patients)
11/24 (45.8%) 1015
patient-d
18/39 (46.1%) Not
available
Success rate of
BTT/BTR
17/24 (70.8%) 27/39 (69.2%)
LVAD 14/19 (73.7%) 19/24 (79.1%)
BVAD 3/5 (60%) 8/15 (53.3%)
Readmission 7 patients with 9
episodes
10 patients with 15
episodes
Neurologic
CVA 3/24 (12.5%) 3/39 (7.7%)
TIA 0.94 patient-y 1.94 patient-y
Infection
Pocket 1/24 2/39
Drive line 3/24 (12.5%) 5/39 (12.8%)
BTT, Bridge to transplant; CVA, cerebral vascular accident; DCM, dilated cardiomy-
opathy; IHD, ischemic heart disease; PC, postcardiotomy failure; TIA, transient ische-
mic attack. Twelve patients from the Papworth group who received an IVAD before
June 2004 were included in the multicenter study.
Berman et al Cardiothoracic Transplantation
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Xappendicitis (supported by laboratory and computed tomog-
raphy findings) and underwent successful appendectomy.
Mechanical Device Failure
There was no mechanical failure of the IVAD, and no
IVAD required replacement. One patient experienced bat-
tery malfunction with the TLC-II driver failing to switch be-
tween the 2 batteries. He simply swapped over to a backup
driver, which is supplied to all patients.
DISCUSSION
The Thoratec IVAD is the only implantable VAD that can
be used for uni- or biventricular support. In the present se-
ries, 79% of patients required 1 IVAD as LVAD and 21%
of patients required 2 IVADs as biventricular support from
the outset. Among the patients receiving an LVAD, 11%
subsequently required late RVAD support. The overall sur-
vival for the whole series was 70.8%. Of those who only
required LVAD, 82.4% were successfully bridged to trans-
plant (14/17 patients). Those requiring BVAD support from
the outset had a slightly lower survival of 60% (3/5). For the
2 patients receiving an LVAD who required late RVAD sup-
port, mortality was 100%. This confirmed that when re-
quired, early insertion of RVAD at the time of LVAD
implantation provides superior outcome. These results are
consistent with the international multicenter study of the
Thoratec IVAD (Table 3).13
In this series, the smallest patients with a BVAD im-
planted with 2 Thoratec IVADs was a 17-year-old female
weighing 47 kg with a body surface area of 1.63 m2. She
was discharged home on VAD support and was successfully
bridged to transplant after 301 days.
Although the design of the Thoratec IVAD is similar to its
predecessor, the IVAD is aesthetically more acceptable to
patients and caregivers by being intracorporeal. The single
flexible IVAD driveline is easier to manage than the 2 large
percutaneous inflow and outflow cannulae of the PVAD. In
addition, the implanted IVAD has an optical sensor to assess
pump emptying and does not require regular visual checks
with the ‘‘flash test’’ as with the PVAD. Furthermore, by be-
ing implanted inside the abdominal wall, improvised slings
that are necessary to carry the PVAD are no longer required.
These factors all contribute to a higher discharge rate of 46%
in our IVAD series when compared with our PVAD experi-
ence. The single flexible percutaneous driveline of the IVAD
also contributes to a lower exit site infection rate when com-
pared with that of the double exit sites of the larger PVAD
cannulae: infection rate of 0.32 (IVAD) versus 0.61
(PVAD) with a risk ratio of 0.53.13 This probably contrib-
uted to the relatively low rate of deep-seated infections in
this IVAD series.
RV failure remains a serious potential complication of
LVAD implantation. Treatment of RV failure post-LVAD
implantation includes the use of inotropic support, pulmo-The Journal of Thoracic and Canary vasodilatation, or RVAD support. We believe it is im-
portant to prevent the increase in pulmonary vascular
resistance and minimize RV injury during LVAD implanta-
tion. The use of nitric oxide preemptively for all patients
forms part of our routine RV protection strategy.14,15 How-
ever, nitric oxide is routinely weaned within 12 to 24 hours
post-VAD implant, and when necessary, substituted with
nebulized iloprost 3-9 mg every 3 hours, with the dose
adjusted according to response.
The number of patients requiring CVVH post-VAD in-
cluded 3 patients who required CVVH pre-VAD. Two of
5 patients with BiVADs required CVVH post-implant, and
1 patient died of multiorgan system failure.
We think it is important to minimize the central venous
pressure in patients with VADs, particularly in those with
preexisting end-organ dysfunction. As a result, instead of re-
lying on diuretic therapy alone, we have a low threshold for
using CVVH to optimize volume status. This explains the
high rate of CVVH use in our patients with VADs postoper-
atively. Use of CVVH does not indicate renal failure.16
There are special technical considerations when implant-
ing the Thoratec IVAD. Although the dimensions of the
Thoratec IVAD are significantly smaller than those of other
implantable pulsatile devices, the abdominal pump pocket re-
quired to accommodate the IVAD is still considerable, partic-
ularly in its vertical dimension. This is to accommodate therdiovascular Surgery c Volume 139, Number 2 471
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and the connector/inflow valve housing on the IVAD. Failure
to dissect a deep enough pump pocket may cause the IVAD to
ride high, distorting the LV apex, with the risk of compromis-
ing LVAD filling. For this reason, we prefer to use the short-
est available inflow cannula to reduce the size of the required
pump pocket. The hybrid pump pocket takes advantage of the
distensible pre-peritoneal space medially and the resilience of
the posterior rectus sheath laterally.
The curve in the IVAD inflow cannula is designed to
align the mouth of the inflow with the long axis of the
left ventricle, thereby improving LV drainage. However,
it also introduces potential technical pitfalls. For the left
ventricle to drain freely into the IVAD, the ventricular
opening of the inflow cannula must be directed toward
the mitral valve opening, that is, with a 30- to 40-degree
rotation posteromedially. If the inflow cannula is inadver-
tently connected to the IVAD with a 90-degree rotation in-
stead, the opening of the inflow cannula would face the
posterior LV endocardium, leading to poor drainage of
the left ventricle and poor LVAD flows. If the mouth of
the inflow cannula points laterally, the situation is even
worse. This occurred with one of our earlier IVAD im-
plants. Once this situation was recognized, that patient
was returned to the operation room for re-sternotomy and
revision of the inflow cannula orientation. Fortunately, it
was possible to accomplish this revision without putting
the patient back on CPB.
The Thoratec IVAD outflow cannula is a composite be-
tween a Thoralon tube (a Thoratec proprietary polyurethane)
and a Dacron vascular graft. When connecting this outflow
cannula to the IVAD, the curve should point squarely toward
the right of the patient, directing the Dacron graft into a gen-
tle curve toward the right anterolateral surface of the ascend-
ing aorta (Figure 2).
The result from this series confirms that the Thoratec
IVAD is a reliable device for bridging patients to heart trans-
plantation. There was no mechanical failure, allowing major
organ function recovery. The 71% successful bridge to
transplant rate in this series is similar to that reported previ-
ously in the Thoratec IVAD multicenter trial (69%).13 It is
also comparable to the success rate reported with other pul-
satile devices, such as the Thoratec PVAD (65%),17 the
HeartMate IP LVAD (71%),6 and the HeartMate VE
(LVAS, 71%). In this series, patients who required biven-
tricular support at the time of LVAD implant had a lower
survival (60%), consistent with previous studies demon-
strating that patients with increased severity of illness, espe-
cially with renal and hepatic failure, are more likely to
require BVADs and thus be at a higher risk of death than
patients requiring LVAD alone. However, patients im-
planted with an RVAD at the time of LVAD insertion still
fared better than those who had late insertion of RVAD.
All adverse events recorded in this study are commonly en-472 The Journal of Thoracic and Cardiovascular Surgcountered with other implantable VAD. The incidences are
also consistent with those reported previously.12,13
During the study period, our indications for BIVAD were
a) intractable ventricular arrhythmia and b) LVAD flow less
than 2.0 L/min/m2 or right atrial pressure more than 20 mm
Hg.18
More recently, we have lowered our threshold for deploy-
ing RVAD and adjusted our indications to include mixed
venous oxygen saturation less than 60% with right atrial
pressure greater than 16 mm Hg.
There has been tremendous progress in the field of me-
chanical circulatory support during the last 5 years. Recent
results of new rotary LVADs such as the HeartMate II and
the VentrAssist have been excellent.19,20 These smaller de-
vices have now become the first choice for most patients
requiring LVAD support. However, in the decompensated
patients who are unable to undergo transplantation because
of acute end-organ failure, the chances of requiring BVAD
support remains significant, and we continue to select the
Thoratec IVAD in those cases. Other patients in whom we
would preferentially use the IVAD include those with intrac-
table ventricular arrhythmias and those with significant or
predominant RV failure.
CONCLUSIONS
The Thoratec IVAD has demonstrated the capability of
providing univentricular and biventricular support, with an
acceptable complication rate. Extended cardiac support
was provided for as long as 301 days, and approximately
half of the patients were successfully discharged to await
cardiac transplantation.
The authors acknowledge the contribution of Carol Freeman,
research officer, Papworth Hospital, United Kingdom.
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